N@N

51.39% Of All NASDAQ Trading Thursday Was Short Selling. NLTX, ASGR, VIMC, NGBF, ALTU, QDHC Highest % Of Daily Trading Volume

^{Published on 2009-10-08 17:28:05, Last Modified on 2010-12-22 14:53:24 - WOPRAI}
 

October 9, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NASDAQ Daily Short Volume Report for Thursday, October 8th, 2009 and come to the following statistical conclusions. There were 6,689 stocks with daily short volume reported and total NASDAQ trading volume of 1,782,963,499 shares. Total Daily Short Volume was 916,352,704 shares. 51.39% of all trading on the NASDAQ Thursday was short selling. The chart below highlights 6 stocks that had unusually high percentages of their total daily trading volume attributed to short sales. Nile Therapeutics (NASDAQ: NLTX), America Service Group (NASDAQ: ASGR), Vimicro International (NASDAQ: VIMC), New Generation Biofuels (NASDAQ: NGBF), Altus Pharmaceuticals (NASDAQ: ALTU) and Quadramed (NASDAQ: QDHC). To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

DATE SYMBOL SHORT VOLUME TOTAL VOLUME MARKET PERCENT

20091008 NLTX 110,664 117,040 Q 94.55%

20091008 ASGR 122,254 135,454 Q 90.25%

20091008 VIMC 58,094 64,867 Q 89.56%

20091008 NGBF 167,080 203,345 Q 82.17%

20091008 ALTU 169,281 215,291 Q 78.63%

20091008 QDHC 83,200 107,450 Q 77.43%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

Nile Therapeutics, Inc. (NASDAQ: NLTX), a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for the treatment of cardiovascular disease and other areas of unmet medical needs. The company focuses on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. Nile is also developing CU-NP, a novel, rationally designed natriuretic peptide. The company was founded in 2005 and is based in San Francisco, California.

America Service Group Inc. (NASDAQ: ASGR), through its subsidiaries, provides managed healthcare services to correctional facilities in the United States. It contracts with state, county, and local governmental agencies to provide and/or administer healthcare services to inmates of prisons and jails. The companya�s on-site medical services include physical and mental health screening, such as the compilation of the inmatea�s health history and the identification of current, chronic, or acute healthcare needs; and regular physical and dental screening and care, psychiatric care, OB-GYN screening and care, and diagnostic testing. America Service Groupa�s off-site medical services comprise specialty outpatient diagnostic testing and care, emergency room care, surgery, and hospitalization. It also provides on-site administrative support services, including program management, maintenance of on-site medical records and employee recruitment, scheduling, continuing education and quality assurance, medical audits, credentialing, and clinical program development activities. America Service Group Inc. was founded in 1978 and is headquartered in Brentwood, Tennessee with additional offices in Alameda, California; Lansing, Michigan; Verona, New Jersey; Astoria, New York; Camp Hill, Pennsylvania; Richmond, Virginia; and Burlington, Vermont.

Vimicro International Corporation (NASDAQ: VIMC), through its subsidiaries, designs, develops, and markets mixed-signal semiconductor products and system-level solutions for the consumer electronics, communications, and surveillance markets. It offers mixed-signal multimedia processors for personal computer and embedded notebook cameras, as well as for mobile phones. The company provides system-level solutions that include integrated semiconductors, customizable firmware and software, software development tools, reference designs, and applications support. It also involves in packaging, testing, and reselling third party image sensors. Vimicro International sells its products through direct sales force and distributors to original equipment manufacturers, design houses, and module manufacturers in Mainland China and Hong Kong. It has a strategic collaboration agreement with Leadcore Technology Co. Ltd. to develop 3G mobile phone technologies based on TD-SCDMA and multimedia standards for China Mobile. The company was founded in 1999 and is headquartered in Beijing, the Peoplea�s Republic of China.

New Generation Biofuels Holdings, Inc. (NASDAQ: NGBF), through its subsidiary, New Generation Biofuels, Inc., holds an exclusive license to commercialize proprietary technology to manufacture an alternative bio-fuel from vegetable oils and animal fats in North America, Central America, and the Caribbean. It offers its bio-fuel or fuel additive for use in diesel fuel applications, including power generation, commercial and industrial heating, and marine transportation. The company was formerly known as H2Diesel Holdings, Inc. and changed its name to New Generation Biofuels Holdings, Inc. in March 2008. New Generation Biofuels Holdings was founded in 2006 and is headquartered in Columbia, Maryland.

Altus Pharmaceuticals Inc. (NASDAQ: ALTU), together with its subsidiaries, focuses on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. Its lead product candidates include ALTU-238, completed Phase II clinical trial in adults, is a crystallized formulation of human growth hormone for the treatment of hormone deficiency and related disorders; and ALTU-237, completed Phase I clinical trial, which is used for the treatment of hyperoxalurias and kidney stones. The companya�s preclinical research and development programs include ALTU-236, an orally-administered enzyme replacement therapy product candidate designed to reduce the long-term effects associated with excess levels of phenylalanine; and ALTU-242, an orally-administered enzyme product candidate designed to reduce the long-term effects associated with excess levels of urate, which precipitates and forms crystals in joints causing a painful erosive arthritis, known as gout. Its product candidates are designed to substitute a protein that is in short supply in the body, degrade toxic metabolites in the gut, and remove them from the blood stream. Altus Pharmaceuticals has a license agreement with Cystic Fibrosis Foundation Therapeutics, Inc. to use its intellectual property to develop, manufacture, and commercialize any product using, in any combination, the three active pharmaceutical ingredients which comprise Trizytek. Altus Pharmaceuticals Inc. was formerly known as Altus Biologics Inc. and changed its name to Altus Pharmaceuticals Inc. in May 2004. The company was incorporated in 1992 and is based in Waltham, Massachusetts.

QuadraMed Corporation (NASDAQ: QDHC), together with its subsidiaries, provides information technology solutions for healthcare enterprises primarily in the United States, Puerto Rico, Canada, Saudi Arabia, and the United Kingdom. The companya�s product offerings include QuadraMed Care Management Solutions, which enable healthcare organizations to reach their electronic health record with integrated, workflow-driven solutions that enable clinicians to organize and manage patient care activities, access patient information, and document; QuadraMed Patient Revenue Management Solutions designed to facilitate billing; QuadraMed Health Information Management (HIM) Solutions suite includes electronic documentation management, workflow, electronic signature, and QuadraMed File Manager solutions, which enables healthcare organizations to manage information critical processes within their facilities. Its HIM solutions also offers eSignature product that allows physicians to electronically sign their clinical reports and route them upon completion. In addition, the companya�s product offerings include QuadraMed Access and Identity Management Solutions, which identifies, corrects, and prevents the creation of duplicate patient records; and Governmental Solutions that provide value across the VA Medical Center network for data integrity and productivity through coding tools, compliance monitoring, and customizable billing, as well as coding edits, electronic work assignment, and reporting for inpatient and outpatient encounters. QuadraMed Corporation also provides professional services, including implementation, project management, support, consulting, technical assistance, and end-user training. It markets its products to acute care hospitals, multifacility care delivery organizations, and specialty hospitals, as well as to Veterana�s Health Administration facilities. The company was founded in 1993 and is headquartered in Reston, Virginia.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net